Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 8.01, 9.01 · 8-K

TriSalus Life Sciences, Inc.

TLSINASDAQEQUITYCurrent

Other Events

Item 8.01 Other Events. On September 22, 2026, TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing that it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its TriNav Advance device. With FDA clearance, the Company expects to commence commercialization.…

Filed Sep 22, 2026Accepted Sep 22, 2026, 4:14 PM EDTCIK 1826667Accession 0001628280-26-063031
Share

Company context

Current securities

Historical securities (3)

Recent company filings

  1. 10-Q filingAug 6, 2026
  2. Results of Operations and Financial ConditionAug 6, 2026
  3. 4 filingJul 6, 2026
  4. 4 filingJul 1, 2026
  5. 5 filingJul 1, 2026

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. On September 22, 2026, TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing that it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its TriNav Advance device. With FDA clearance, the Company expects to commence commercialization. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.